Glucagon immunoreactivities and amino acid profile in plasma of duodenopancreatectomized patients. 1979

W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold

Glucogon immunoreactivity (IRG) was measured in plasma of duodenopancreatectomized subjects with a nonspecific (K-4023) and a specific (30-K) glucagon antiserum. After an overnight fast, plasma IRG (K-4023) was significantly (P < 0.05) higher in the subjects without pancreas, averaging 782+/-79 (SEM) pgeq/ml, than in the controls (482+/-80 pgeq/ml). IRG (30-K) of 162+/-68 pg/ml did not change during an infusion of arginine (450 mg/kg per 40 min). Insulin deprivation during 3 d in one patient did not restore the IRG response to arginine as reported in depancreatized dogs.Bio-Gel P-30 column chromatography revealed that virtually all IRG (30-K) measured in whole plasma was of different molecular weight than glucagon, and primarily of a mol wt >/= 40,000. Intravenous arginine did not significantly alter the chromatographic pattern of these plasmas. Thus, as postulated by others, duodeno-pancreatectomized humans have virtually no circulating 3,500-dalton glucagon. Hence, the presence of 3,500-dalton glucagon in plasma is not a condition for the diabetic state. It might, nevertheless, when present in normal or excessive amounts, worsen the metabolic state of diabetic patients. Among 14 amino acids measured in plasma of these patients, the concentrations of alanine, serine, ornithine, and arginine were significantly (P < 0.05) elevated to approximately twice that of normal: alanine and serine are both substrates for gluconeogenesis, whereas ornithine and arginine are involved in the formation of urea, the second product of hepatic gluconeogenesis. As the concentrations of branched chain amino acids were not grossly altered, it is hypothesized that this amino acid pattern is a consequence of glucagon deficiency rather than secondary to the diabetic state of these patients.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007657 Ketone Bodies The metabolic substances ACETONE; 3-HYDROXYBUTYRIC ACID; and acetoacetic acid (ACETOACETATES). They are produced in the liver and kidney during FATTY ACIDS oxidation and used as a source of energy by the heart, muscle and brain. Acetone Bodies,Bodies, Acetone,Bodies, Ketone
D007773 Lactates Salts or esters of LACTIC ACID containing the general formula CH3CHOHCOOR.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010180 Pancreatectomy Surgical removal of the pancreas. (Dorland, 28th ed) Pancreatectomies
D011183 Postoperative Complications Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. Complication, Postoperative,Complications, Postoperative,Postoperative Complication
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004386 Duodenum The shortest and widest portion of the SMALL INTESTINE adjacent to the PYLORUS of the STOMACH. It is named for having the length equal to about the width of 12 fingers. Duodenums

Related Publications

W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold
April 1983, European journal of clinical investigation,
W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold
August 1980, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold
August 2005, Seminars in cancer biology,
W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold
May 1985, Annales medico-psychologiques,
W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold
January 2017, Scientific reports,
W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold
January 2000, Blood purification,
W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold
October 2012, Pregnancy hypertension,
W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold
November 1973, The Journal of clinical investigation,
W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold
March 2016, European review for medical and pharmacological sciences,
W A Muller, and M Berger, and P Suter, and H J Cüppers, and J Reiter, and T Wyss, and P Berchtold, and F H Schmidt, and J P Assal, and A E Renold
January 2022, Current HIV research,
Copied contents to your clipboard!